Verrica Pharmaceuticals Inc. - Common Stock (VRCA)
2.9100
+0.0300 (1.04%)
NASDAQ · Last Trade: Nov 20th, 10:20 AM EST
Detailed Quote
| Previous Close | 2.880 |
|---|---|
| Open | 2.880 |
| Bid | 2.890 |
| Ask | 3.050 |
| Day's Range | 2.880 - 2.910 |
| 52 Week Range | 2.770 - 9.821 |
| Volume | 2,045 |
| Market Cap | 122.10M |
| PE Ratio (TTM) | -1.265 |
| EPS (TTM) | -2.3 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 58,807 |
Chart
About Verrica Pharmaceuticals Inc. - Common Stock (VRCA)
Verrica Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing innovative treatments for dermatological conditions, particularly for skin diseases like warts and other cutaneous manifestations. The company is dedicated to advancing its proprietary product candidates that utilize a unique approach to deliver targeted therapies, aiming to improve patient outcomes and enhance the quality of life for individuals suffering from these conditions. By leveraging its expertise and cutting-edge technology, Verrica is committed to addressing unmet medical needs within the dermatology space. Read More
News & Press Releases
YCANTH sales hit a record while Gorlin syndrome becomes a new target.
Via The Motley Fool · November 13, 2026
Verrica Pharmaceuticals (NASDAQ:VRCA) reported record quarterly U.S. revenue for its molluscum treatment YCANTH in the third quarter of 2026, even as total revenue fell from a year earlier and its net loss widened.
The company also outlined plans to explore its experimental drug VP-315 in patients
Via MarketBeat · November 13, 2026
– Company reports record U.S. YCANTH net product revenue of $5.7 million in Q3 2026, up 11.9% over the previous quarter and 57.9% year-over-year, and total revenue of $6.9 million –
By Verrica Pharmaceuticals Inc. · Via GlobeNewswire · November 12, 2026
WEST CHESTER, Pa., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the Jefferies Global Healthcare Conference in London.
By Verrica Pharmaceuticals Inc. · Via GlobeNewswire · November 10, 2026
Verrica Pharmaceuticals (NASDAQ:VRCA) Q1 Results Beat Revenue Estimates as Pipeline Progress and Record Demand Drive Positive Momentumchartmill.com
Via Chartmill · May 12, 2026
WEST CHESTER, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Thursday, November 12, 2026, to discuss the Company's financial results for the third quarter ending September 30, 2026, and provide a corporate update.
By Verrica Pharmaceuticals Inc. · Via GlobeNewswire · November 5, 2026
– Company’s achievement of pre-defined revenue, growth and operational milestones increases facility commitment by $15.0 million –
By Verrica Pharmaceuticals Inc. · Via GlobeNewswire · October 22, 2026
– Analysis shows YCANTH achieved complete clearance of molluscum contagiosum approximately 4 times faster than vehicle, regardless of disease duration –
By Verrica Pharmaceuticals Inc. · Via GlobeNewswire · September 30, 2026
– Post-hoc analysis shows YCANTH® drove high rates of complete clearance in molluscum contagiosum patients regardless of disease duration –
By Verrica Pharmaceuticals Inc. · Via GlobeNewswire · September 10, 2026
WEST CHESTER, Pa., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the H.C. Wainwright 28th Annual Global Investment Conference.
By Verrica Pharmaceuticals Inc. · Via GlobeNewswire · September 8, 2026
– Per-protocol interim statistical power analysis confirms no additional patients are recommended for full enrollment –
By Verrica Pharmaceuticals Inc. · Via GlobeNewswire · August 27, 2026
YCANTH dispensed units surged 28% sequentially as the company secured $27.5M in financing.
Via The Motley Fool · August 13, 2026
Verrica Pharmaceuticals (NASDAQ:VRCA) reported second-quarter revenue growth in its YCANTH treatment for molluscum contagiosum, while outlining progress in pivotal studies of the product for common warts and announcing a credit facility that management said could extend its cash runway into 2028.
C
Via MarketBeat · August 7, 2026
– Company reports record demand for YCANTH® as dispensed applicator units grew to 19,626 in Q2 2026, up 28.3% over the previous quarter and 46.1% year-over-year –
By Verrica Pharmaceuticals Inc. · Via GlobeNewswire · August 6, 2026
— Facility will support YCANTH® commercialization, global Phase 3 program for YCANTH® in common warts and general corporate operations —
By Verrica Pharmaceuticals Inc. · Via GlobeNewswire · August 6, 2026
WEST CHESTER, Pa., July 30, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Thursday, August 6, 2026, to discuss the Company's financial results for the second quarter ending June 30, 2026, and provide a corporate update.
By Verrica Pharmaceuticals Inc. · Via GlobeNewswire · July 30, 2026
WEST CHESTER, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced an exclusive distribution, marketing and supply agreement (“the Agreement”) granting Medomie Pharma Ltd. (“Medomie”) rights to seek regulatory approval for and distribute YCANTH® for the treatment of molluscum contagiosum (“molluscum”) in Israel.
By Verrica Pharmaceuticals Inc. · Via GlobeNewswire · July 21, 2026
– Development Partner Torii Pharmaceutical also recently announced dosing of the first Japanese patient in this trial evaluating YCANTH (TO-208) in Japan –
By Verrica Pharmaceuticals Inc. · Via GlobeNewswire · June 22, 2026
WEST CHESTER, Pa., May 28, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the Jefferies Global Healthcare Conference.
By Verrica Pharmaceuticals Inc. · Via GlobeNewswire · May 28, 2026
Verrica (VRCA) Q1 2026 Earnings Transcript
Via The Motley Fool · May 13, 2026
WEST CHESTER, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ.
By Verrica Pharmaceuticals Inc. · Via GlobeNewswire · May 13, 2026
Verrica Pharmaceuticals (NASDAQ:VRCA) reported higher first-quarter revenue and record demand for its molluscum contagiosum treatment YCANTH, while outlining progress on late-stage development programs in common warts and basal cell carcinoma.
President and Chief Executive Officer Jayson Rieger sai
Via MarketBeat · May 12, 2026
– Company reports record demand for YCANTH® as dispensed applicator units grew to 15,302 in Q1 2026, up 12.1% over the previous quarter and 51.3% year-over-year, and has now exceeded 100,000 dispensed applicator units since launch –
By Verrica Pharmaceuticals Inc. · Via GlobeNewswire · May 12, 2026
Phase 2 Data Highlight the Observed Abscopal-like Effect of VP-315 in Non-treated Basal Cell Carcinoma Tumors
By Verrica Pharmaceuticals Inc. · Via GlobeNewswire · May 5, 2026
WEST CHESTER, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Tuesday, May 12, 2026, to discuss the Company's financial results for the first quarter ending March 31, 2026, and provide a corporate update.
By Verrica Pharmaceuticals Inc. · Via GlobeNewswire · May 5, 2026